CSF β-amyloid predicts prognosis in patients with multiple sclerosis

Anna M. Pietroboni, Michela Caprioli, Tiziana Carandini, Marta Scarioni, Laura Ghezzi, Andrea Arighi, Sara Cioffi, Claudia Cinnante, Chiara Fenoglio, Emanuela Oldoni, Milena A. De Riz, Paola Basilico, Giorgio G. Fumagalli, Annalisa Colombi, Giovanni Giulietti, Laura Serra, Fabio Triulzi, Marco Bozzali, Elio Scarpini, Daniela Galimberti

Research output: Contribution to journalArticlepeer-review


Background: The importance of predicting disease progression in multiple sclerosis (MS) has increasingly been recognized, and hence reliable biomarkers are needed. Objectives: To investigate the prognostic role of cerebrospinal fluid (CSF) amyloid beta1–42 (Aβ) levels by the determination of a cut-off value to classify patients in slow and fast progressors. To evaluate possible association with white matter (WM) and grey matter (GM) damage at early disease stages. Methods: Sixty patients were recruited and followed up for 3–5 years. Patients underwent clinical assessment, brain magnetic resonance imaging (MRI; at baseline and after 1 year), and CSF analysis to determine Aβ levels. T1-weighted volumes were calculated. T2-weighted scans were used to quantify WM lesion loads. Results: Lower CSF Aβ levels were observed in patients with a worse follow-up Expanded Disability Status Scale (EDSS; r = −0.65, p < 0.001). The multiple regression analysis confirmed CSF Aβ concentration as a predictor of patients’ EDSS increase (r = −0.59, p < 0.0001). Generating a receiver operating characteristic curve, a cut-off value of 813 pg/mL was determined as the threshold able to identify patients with worse prognosis (95% confidence interval (CI): 0.690–0.933, p = 0.0001). No differences in CSF tau and neurofilament light chain (NfL) levels were observed (p > 0.05). Conclusion: Low CSF Aβ levels may represent a predictive biomarker of disease progression in MS.

Original languageEnglish
JournalMultiple Sclerosis Journal
Publication statusAccepted/In press - Jan 1 2018


  • Biomarkers
  • MRI
  • multiple sclerosis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'CSF β-amyloid predicts prognosis in patients with multiple sclerosis'. Together they form a unique fingerprint.

Cite this